AMSBIO reports on a recent published paper** by the Howard Hughes Medical Institute at the Massachusetts Institute of Technology (MIT) investigating why epithelial cells grown in monolayers on a plastic dish are worse at segregating their chromosomes than epithelial cells in vivo or in 3D organoid cultures.
This discovery by the MIT researchers could have big implications for scientists growing human tissues in the lab and may also help explain why chromosome mistakes run rampant in cancerous cells – an unanswered question in cancer biology. More broadly, the new findings demonstrate that cells should be studied in the right context by moving on from culturing cells in two dimensions on a plastic dish, to grow them in 3D, mimicking normal development in organoid culture systems.

Mature (96-hour) epithelial organoid, stained with phalloidin to label actin in green and Hoechst to label DNA in blue. (Image courtesy of Kristin Knouse, Howard Hughes Medical Institute, MIT
The MIT researchers used RNA Stat-60 from AMSBIO to extract total RNA for sequencing from immature and mature organoids. Their analysis of gene expression demonstrated that tissue architecture influences chromosome segregation in a post-transcriptional manner.
William Hadlington-Booth - a business unit manager at AMSBIO said "As a leading supplier in organoid culture, it’s exciting to see our trusted reagent RNA Stat-60 being used for studying gene expression in such an innovative research project at MIT. It adds to our comprehensive range of products assisting organoid customers including matrices, growth factors and cryropreservation reagents"

Kristin Knouse (lead author of the paper) joined the Howard Hughes Medical Institute as a Whitehead Fellow in June 2018, and won the NIH Early Independence Award in the same year.
For further information on RNA Stat-60 please visit
http://www.amsbio.com/rna-stat60.aspx. For further information on AMSBIO’s unique range of 3D cell culture products please visit
http://www.amsbio.com/cells-3d-cell-culture.aspx or contact the company now on +44-1235-828200 / +1-617-945-5033 / info@amsbio.com.
Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading transatlantic company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for research and development in the medical, nutrition, cosmetics and energy industries. AMSBIO has in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. This expertise in cell culture and the ECM allows AMSBIO to partner with clients in tailoring cell systems to enhance organoid and spheroid screening outcomes using a variety of 3D culture systems, including organ-on-a-chip microfluidics.
For drug discovery research, AMSBIO offers assays, recombinant proteins and cell lines. Drawing upon a huge and comprehensive biorepository, AMSBIO is widely recognised as a leading provider of high-quality tissue specimens (including custom procurement) from both human and animal tissues. The company provides unique clinical grade products for stem cell and cell therapy applications these include high quality solutions for viral delivery (lentivirus, adenovirus and adeno-associated virus) in addition to GMP cryopreservation technology.
** Knouse, Kristin A., et al. "Chromosome segregation fidelity in epithelia requires tissue architecture."
Cell 175.1 (2018): 200-211
Worldwide HQ
AMS Biotechnology (AMSBIO)
184 Milton Park
Abingdon
Oxon OX14 4SE
North American HQ
AMSBIO LLC
1035 Cambridge Street
Cambridge
MA 02141
USA
Tel: +1.617.945.5033
Tel: +1.800.987.0985 (toll free)
Email:
info@amsbio.com Web
www.amsbio.com